MRK Stock Recent News

Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Merck's long-term prospects look strong despite a major incoming patent cliff. Novartis' diversified lineup and pipeline, solid results, and dividend record make it an excellent pick.

Merck (MRK) stock is being driven by the strong sales of key products like Keytruda and Gardasil and positive pipeline and regulatory developments.

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Share New Research and Host Community-Focused Symposia at AIDS 2024.

Merck's price rise might have stalled in the past quarter, but at least for now, there's potential for some upswing again. Keytruda continues to drive revenue growth, and expansion in its usage along with positive news on other treatments and an acquisition related bump up too, the sales outlook is healthy. Concerns arise, however, regarding the earnings outlook due to the acquisition of Eyebiotech, which can impact non-GAAP EPS and potentially reduce guidance.

Merck (MRK) reachead $126.04 at the closing of the latest trading day, reflecting a +0.21% change compared to its last close.

Cigna, Merck, Toll Brothers, Medtronic could see shares gain after proving their earnings growth remains strong.

Merck (MRK) exercises the option that will convert the collaboration deal with partner Orion for prostate cancer candidate opevesostat into a license agreement.

Merck's (MRK) Winrevair is poised to become the first activin signaling inhibitor therapy for PAH in Europe if approved by the European Commission.